NASDAQ:RVPH Reviva Pharmaceuticals (RVPH) Stock Forecast, Price & News $5.05 +0.22 (+4.55%) (As of 09/28/2023 ET) Add Compare Share Share Today's Range$4.84▼$5.2550-Day Range$3.91▼$5.9052-Week Range$1.56▼$9.25Volume77,096 shsAverage Volume130,943 shsMarket Capitalization$114.38 millionP/E RatioN/ADividend YieldN/APrice Target$14.60 ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial MediaProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media Reviva Pharmaceuticals MarketRank™ ForecastAnalyst RatingBuy3.00 Rating ScoreUpside/Downside189.1% Upside$14.60 Price TargetShort InterestBearish6.49% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.39Based on 11 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($1.41) to ($1.01) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.1.93 out of 5 starsMedical Sector696th out of 969 stocksPharmaceutical Preparations Industry328th out of 453 stocks 3.5 Analyst's Opinion Consensus RatingReviva Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 6 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $14.60, Reviva Pharmaceuticals has a forecasted upside of 189.1% from its current price of $5.05.Amount of Analyst CoverageReviva Pharmaceuticals has only been the subject of 3 research reports in the past 90 days. Previous Next 1.0 Short Interest Percentage of Shares Shorted6.49% of the outstanding shares of Reviva Pharmaceuticals have been sold short.Short Interest Ratio / Days to CoverReviva Pharmaceuticals has a short interest ratio ("days to cover") of 8.9.Change versus previous monthShort interest in Reviva Pharmaceuticals has recently increased by 13.95%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldReviva Pharmaceuticals does not currently pay a dividend.Dividend GrowthReviva Pharmaceuticals does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for RVPH. Previous Next 3.0 News and Social Media Coverage News SentimentReviva Pharmaceuticals has a news sentiment score of 0.39. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.67 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 11 news articles for Reviva Pharmaceuticals this week, compared to 1 article on an average week.Search Interest8 people have searched for RVPH on MarketBeat in the last 30 days. This is an increase of 167% compared to the previous 30 days.MarketBeat Follows4 people have added Reviva Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is an increase of 300% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Reviva Pharmaceuticals insiders have not sold or bought any company stock.Percentage Held by Insiders32.06% of the stock of Reviva Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 24.09% of the stock of Reviva Pharmaceuticals is held by institutions. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Reviva Pharmaceuticals are expected to grow in the coming year, from ($1.41) to ($1.01) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Reviva Pharmaceuticals is -3.58, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Reviva Pharmaceuticals is -3.58, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioReviva Pharmaceuticals has a P/B Ratio of 8.42. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Reviva Pharmaceuticals (NASDAQ:RVPH) StockReviva Pharmaceuticals Holdings, Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes next-generation therapeutics for diseases targeting unmet medical needs in the areas of central nervous system, respiratory, cardiovascular, metabolic, and inflammatory diseases. The company's lead product candidate is brilaroxazine (RP5063), which is in Phase III clinical trials for the treatment of schizophrenia, as well as completed Phase I clinical trials to treat bipolar disorder, major depressive disorder, attentiondeficit/hyperactivity disorder, behavioral and psychotic symptoms of dementia or Alzheimer's disease, Parkinson's disease psychosis, attention deficit hyperactivity disorder, pulmonary arterial hypertension, and idiopathic pulmonary fibrosis. It is also developing RP1208 that is in pre-clinical development studies for the treatment of depression and obesity. The company is based in Cupertino, California.Read More RVPH Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart RVPH Stock News HeadlinesSeptember 27, 2023 | msn.comReviva Pharmaceuticals: A Binary Event Approaches With Results From RECOVERSeptember 26, 2023 | markets.businessinsider.comReviva Pharmaceuticals Holdings: A Promising Investment Based on Successful Brilaroxazine Schizophrenia StudiesSeptember 29, 2023 | Micro-Cap Stock Trader (Ad)U.S. drive to onshore battery supply chains could create big winners in lithiumInvestor Find Lithium Gold and Crush the Bear Market with 32k Metric TonsSeptember 25, 2023 | finance.yahoo.comReviva Announces Last Patient Evaluated in Pivotal Phase 3 RECOVER Trial for Brilaroxazine in SchizophreniaSeptember 25, 2023 | americanbankingnews.comReviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH) Receives $14.60 Consensus PT from BrokeragesSeptember 23, 2023 | americanbankingnews.comReviva Pharmaceuticals' (RVPH) "Buy" Rating Reiterated at Roth CapitalSeptember 22, 2023 | finanznachrichten.deReviva Pharmaceuticals Holdings, Inc. and Aridis Pharmaceuticals, Inc. Interviews to Air on the RedChip Money Report on Bloomberg TVSeptember 22, 2023 | finance.yahoo.comReviva Pharmaceuticals Holdings, Inc. and Aridis Pharmaceuticals, Inc. Interviews to Air on the RedChip Money Report(R) on Bloomberg TVSeptember 29, 2023 | Micro-Cap Stock Trader (Ad)U.S. drive to onshore battery supply chains could create big winners in lithiumInvestor Find Lithium Gold and Crush the Bear Market with 32k Metric TonsSeptember 22, 2023 | americanbankingnews.comRoth Mkm Initiates Coverage on Reviva Pharmaceuticals (NASDAQ:RVPH)September 20, 2023 | msn.comRoth MKM Initiates Coverage of Reviva Pharmaceuticals Holdings (RVPH) with Buy RecommendationSeptember 20, 2023 | markets.businessinsider.comReviva Pharmaceuticals Holdings (RVPH) Receives a New Rating from Roth MKMSeptember 7, 2023 | finance.yahoo.comReviva to Participate in the H.C. Wainwright 25th Annual Global Investment ConferenceAugust 18, 2023 | finance.yahoo.comRVPH: RECOVER Enrollment CompleteAugust 17, 2023 | finance.yahoo.comReviva Announces Enrollment Completion for Pivotal Phase 3 RECOVER Study for Brilaroxazine in SchizophreniaAugust 16, 2023 | finance.yahoo.comWe're A Little Worried About Reviva Pharmaceuticals Holdings' (NASDAQ:RVPH) Cash Burn RateAugust 14, 2023 | finance.yahoo.comReviva Reports Second Quarter 2023 Financial Results and Recent Business HighlightsJuly 31, 2023 | finance.yahoo.comReviva Pharmaceuticals to Present at Upcoming Investor Conferences in AugustJune 26, 2023 | markets.businessinsider.comH.C. Wainwright Remains a Buy on Reviva Pharmaceuticals Holdings (RVPH)June 26, 2023 | markets.businessinsider.comExpert Ratings for Reviva PharmaceuticalsJune 26, 2023 | finance.yahoo.comReviva Pharmaceuticals to be Added to Russell Microcap® IndexJune 22, 2023 | finance.yahoo.comReviva Pharmaceuticals Announces 80% Global Enrollment Update for Pivotal Phase 3 RECOVER Study Evaluating Brilaroxazine for SchizophreniaJune 15, 2023 | finance.yahoo.comReviva Pharmaceuticals to Present at Upcoming Investor Conferences in JuneJune 9, 2023 | msn.comBenchmark Initiates Coverage of Reviva Pharmaceuticals Holdings (RVPH) with Speculative Buy RecommendationJune 8, 2023 | markets.businessinsider.comWhere Reviva Pharmaceuticals Stands With AnalystsMay 25, 2023 | finance.yahoo.comReviva Pharmaceuticals Announced Preclinical Efficacy Data on Brilaroxazine in IPF at the 2023 American Thoracic Society International Conference and Publication in Medical Research ArchivesMay 22, 2023 | finance.yahoo.comReviva Pharmaceuticals Announces Presentation of Clinical Pharmacology Studies Data on Brilaroxazine at the ASPET 2023 Annual MeetingSee More Headlines Receive RVPH Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Reviva Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address RVPH Company Calendar Last Earnings8/14/2023Today9/29/2023Next Earnings (Estimated)11/13/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:RVPH CUSIPN/A CIK1742927 Webwww.revivapharma.com Phone(408) 501-8881FaxN/AEmployees10Year FoundedN/APrice Target and Rating Average Stock Price Forecast$14.60 High Stock Price Forecast$18.00 Low Stock Price Forecast$10.00 Forecasted Upside/Downside+189.1%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage6 Analysts Profitability EPS (Most Recent Fiscal Year)($1.41) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-24,340,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-306.16% Return on Assets-181.24% Debt Debt-to-Equity RatioN/A Current Ratio1.29 Quick Ratio1.29 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$0.60 per share Price / Book8.42Miscellaneous Outstanding Shares22,650,000Free Float15,388,000Market Cap$114.38 million OptionableNot Optionable Beta0.11 10 "Recession Proof" Stocks That Will Thrive in Any MarketWhich stocks are likely to thrive in today's challenging market? Click the link below and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.Get This Free Report Key ExecutivesDr. Laxminarayan Bhat Ph.D. (Age 58)Founder, CEO, Pres & Director Comp: $560kMr. Narayan Prabhu (Age 51)Chief Financial Officer Comp: $412.5kKey CompetitorsVaccitechNASDAQ:VACCOramed PharmaceuticalsNASDAQ:ORMPCue BiopharmaNASDAQ:CUEGalectin TherapeuticsNASDAQ:GALTMediciNovaNASDAQ:MNOVView All CompetitorsInsiders & InstitutionsColony Group LLCBought 62,000 shares on 8/15/2023Ownership: 0.758%Citadel Advisors LLCBought 67,300 shares on 8/15/2023Ownership: 0.000%Wells Fargo & Company MNBought 5,005 shares on 8/15/2023Ownership: 0.025%Tower Research Capital LLC TRC Bought 9,590 shares on 8/14/2023Ownership: 0.054%BlackRock Inc.Bought 5,052 shares on 8/11/2023Ownership: 0.440%View All Insider TransactionsView All Institutional Transactions RVPH Stock - Frequently Asked Questions Should I buy or sell Reviva Pharmaceuticals stock right now? 6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Reviva Pharmaceuticals in the last year. There are currently 6 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" RVPH shares. View RVPH analyst ratings or view top-rated stocks. What is Reviva Pharmaceuticals' stock price forecast for 2023? 6 brokerages have issued 1 year price objectives for Reviva Pharmaceuticals' shares. Their RVPH share price forecasts range from $10.00 to $18.00. On average, they anticipate the company's stock price to reach $14.60 in the next year. This suggests a possible upside of 189.1% from the stock's current price. View analysts price targets for RVPH or view top-rated stocks among Wall Street analysts. How have RVPH shares performed in 2023? Reviva Pharmaceuticals' stock was trading at $4.25 at the beginning of 2023. Since then, RVPH stock has increased by 18.8% and is now trading at $5.05. View the best growth stocks for 2023 here. When is Reviva Pharmaceuticals' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, November 13th 2023. View our RVPH earnings forecast. How were Reviva Pharmaceuticals' earnings last quarter? Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH) posted its quarterly earnings results on Monday, August, 14th. The company reported ($0.55) EPS for the quarter, missing the consensus estimate of ($0.29) by $0.26. What is Reviva Pharmaceuticals' stock symbol? Reviva Pharmaceuticals trades on the NASDAQ under the ticker symbol "RVPH." How do I buy shares of Reviva Pharmaceuticals? Shares of RVPH stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Reviva Pharmaceuticals' stock price today? One share of RVPH stock can currently be purchased for approximately $5.05. How much money does Reviva Pharmaceuticals make? Reviva Pharmaceuticals (NASDAQ:RVPH) has a market capitalization of $114.38 million. The company earns $-24,340,000.00 in net income (profit) each year or ($1.41) on an earnings per share basis. How can I contact Reviva Pharmaceuticals? Reviva Pharmaceuticals' mailing address is 19925 STEVENS CREEK BLVD. SUITE 100, CUPERTINO CA, 95014. The official website for the company is www.revivapharma.com. The company can be reached via phone at (408) 501-8881 or via email at ir.revivapharma.com. This page (NASDAQ:RVPH) was last updated on 9/29/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Reviva Pharmaceuticals Holdings, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.